Thus, it is possible that the loss of CD109 action leads to an irreversible and tumor-suppressive EMT program, as it generates a fully differentiated mesenchymal phenotype, resulting in the loss of tumorigenicity and metastatic ability [40,41]. The gene discussed is CD109; the disease is neoplasm.